MRP4/ABCC4 expression is regulated by histamine in acute myeloid leukemia cells, determining cAMP efflux

Abstract

Intracellular cAMP (i‐cAMP) levels play an important role in acute myeloid leukemia (AML) cell proliferation and differentiation. Its levels are the result of cAMP production, degradation, and exclusion. We have previously described histamine H₂ receptors and MRP4/ABCC4 as two potential targets for AML therapy. Acting through histamine H₂ receptors histamine increases cAMP production/synthesis, while MRP4/ABCC4 is responsible for the exclusion of this cyclic nucleotide. In this study, we show that histamine treatment induces MRP4/ABCC4 expression, augmenting cAMP efflux and that histamine, in combination with MRP inhibitors, is able to reduce AML cell proliferation. Histamine, through histamine H₂ receptor, increases i‐cAMP levels and induces MRP4 transcript and protein levels in U937, KG1a, and HL‐60 cells. Moreover, histamine induces MRP4 promoter activity in HEK293T cells transfected with histamine H₂ receptor (HEK293T‐H₂R). Our results support that the cAMP/Epac‐PKA pathway, and not MEK/ERK nor PI3K/AKT signaling cascades, is involved in histamine mediated upregulation of MRP4 levels. Finally, the addition of histamine potentiates the inhibition of U937, KG1a, and HL‐60 cell proliferation induced by MRP4 inhibitors. Our data highlight that the use of a poly‐pharmacological approach aimed at different molecular targets would be beneficial in AML treatment.